(Q34292429)

English

Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

author name string

Porte D Jr

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2001

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

181-188

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Carbohydrate metabolism in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Insulin secretion in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Insulin responses to glucose: evidence for a two pool system in man

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Kinetics of glucose disposal in whole body and across the forearm in man.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Free fatty acids, insulin resistance, and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Effects of fat on insulin-stimulated carbohydrate metabolism in normal men

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible?

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Fasting serum insulin concentration and early insulin response as risk determinants for developing diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Antepartum predictors of the development of type 2 diabetes in Latino women 11-26 months after pregnancies complicated by gestational diabetes

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Decreased Insulin Secretion and Increased Insulin Resistance Are Independently Related to the 7-Year Risk of NIDDM in Mexican-Americans

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Relationships Between Fasting Plasma Glucose Levels and Insulin Secretion During Intravenous Glucose Tolerance Tests

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Relationship Between the Plasma Insulin Response to Oral Glucose and Insulin-stimulated Glucose Utilization in Normal Subjects

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Hyperglycemia and microvascular and macrovascular disease in diabetes

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Biguanides and NIDDM

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Oral antidiabetic agents. A guide to selection

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Acarbose: its role in the treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

The postprandial state and the risk of atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Protein kinase C activation and the development of diabetic complications

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin.

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Sulfonylurea receptors and mechanism of sulfonylurea action

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Glucose toxicity

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Forskolin-Induced Desensitization of Pancreatic β-Cell Insulin Secretory Responsiveness: Possible Involvement of Impaired Information Flow in the Inositol-Lipid Cycle*

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Decreased Sensitivity of the Pancreatic Beta Cells to Glucose in Prediabetic and Diabetic Subjects: A Glucose Dose-Response Study

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Consensus Development Conference on Insulin Resistance. 5-6 November 1997. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Acarbose-induced hepatic injury

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Hepatocellular injury in a patient receiving rosiglitazone. A case report

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Hepatic failure in a patient taking rosiglitazone

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure

1 reference

https://api.crossref.org/works/10.1002%2F1520-7560%28200105%2F06%2917%3A3%3C181%3A%3AAID-DMRR197%3E3.0.CO%3B2-1

21 January 2018

Identifiers

10.1002/1520-7560(200105/06)17:3<181::AID-DMRR197>3.0.CO;2-1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34292429&oldid=2038822059"